As of May 16, 2018 Array Biopharma Inc (NASDAQ:ARRY) Shorts Reduced By 4.58%

May 16, 2018 - By Russell Jones

Array BioPharma Inc. (NASDAQ:ARRY) Corporate Logo

During 2017 Q4 the big money sentiment increased to 1.3. That’s change of 0.09, from 2017Q3’s 1.21. 20 investors sold all, 50 reduced holdings as Array BioPharma Inc. ratio improved. 64 grew positions while 27 funds amassed positions. Funds hold 194.11 million shares thus 1.73% more from 2017Q3’s 190.80 million shares.
Loring Wolcott & Coolidge Fiduciary Llp Ma holds 6,000 shs. Alps Inc holds 218,328 shs or 0.02% of its capital. Driehaus Ltd Co holds 1.22% or 2.51M shs. 283,102 are owned by Aqr Cap Ltd Llc. Balyasny Asset Ltd Llc reported 0.07% in Array BioPharma Inc. (NASDAQ:ARRY). Endurant Cap Mngmt Limited Partnership holds 0.2% of its capital in Array BioPharma Inc. (NASDAQ:ARRY) for 50,600 shs. Shell Asset Mngmt Co stated it has 21,781 shs or 0.01% of all its holdings. Susquehanna Ltd Liability Partnership holds 0% or 520,780 shs in its capital. 295,320 are owned by Columbus Circle Investors. Sphera Funds has invested 0.61% in Array BioPharma Inc. (NASDAQ:ARRY). Rhumbline Advisers stated it has 192,811 shs or 0.01% of all its holdings. Jpmorgan Chase And holds 46,475 shs or 0% of its capital. Janney Montgomery Scott Ltd Co reported 0% of its capital in Array BioPharma Inc. (NASDAQ:ARRY). Kopp Advisors Limited Liability Corp owns 112,662 shs for 1.44% of their capital. The New Jersey-based Nj State Employees Deferred Compensation Plan has invested 0.1% in Array BioPharma Inc. (NASDAQ:ARRY).

Array BioPharma Inc. had 9 sales and 0 insider buys since December 16, 2017. This’s net activity of $16.27 million. $8.90 million worth of Array BioPharma Inc. (NASDAQ:ARRY) shs were sold by Squarer Ron. Sandor Victor sold $133,376 worth of Array BioPharma Inc. (NASDAQ:ARRY) or 8,689 shs on Sunday, April 1. On Tuesday, January 16 Haddock Jason also sold $102,975 worth of Array BioPharma Inc. (NASDAQ:ARRY). Shares for $3.03 million were sold by Robbins Andrew R on Saturday, December 16.

It was showed a decrease on Array Biopharma Inc (NASDAQ:ARRY)’s short interest with 4.58%. It was issued in May by FINRA the 13.08M short interest on ARRY. That’s 4.58% down from 13.70 million shares. Former ARRY’s position will need 7 days to restore. It has 1.88 million average volume. Float short on Array Biopharma Inc is 7.94%.

Ticker’s shares touched $15.55 during the last trading session after 1.24% change.Array BioPharma Inc. has volume of 1.68M shares. Since May 16, 2017 ARRY has risen 68.58% and is uptrending. The stock outperformed the S&P500 by 57.03%.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.The company has $3.23 billion market cap. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus.Last it reported negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Coverage

Total analysts of 5 have positions in Array Biopharma (NASDAQ:ARRY) as follows: 5 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 29, 2017 according to StockzIntelligence Inc Array Biopharma has 10 analyst reports. In Tuesday, February 6 report Stifel Nicolaus maintained it with “Buy” rating and $23.0 target. The company rating was upgraded by Leerink Swann on Monday, January 22. On Wednesday, February 7 the firm earned “Buy” rating by Cowen & Co. In Sunday, January 21 report Stifel Nicolaus maintained it with “Buy” rating and $20.0 target. On Sunday, January 21 the stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Cowen & Co. In Thursday, May 10 report Cowen & Co maintained the stock with “Buy” rating. On Tuesday, February 6 the stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Buy” rating given by Piper Jaffray. On Tuesday, February 6 SunTrust maintained the shares of ARRY in report with “Buy” rating. On Wednesday, November 29 the stock of Array BioPharma Inc. (NASDAQ:ARRY) earned “Buy” rating by Piper Jaffray. On Wednesday, February 7 the stock of Array BioPharma Inc. (NASDAQ:ARRY) has “Outperform” rating given by Leerink Swann.

Another two news for Array BioPharma Inc. (NASDAQ:ARRY) were briefly posted by: Profitconfidential.com on May 14, 2018 with title “ARRY Stock Is Now Primed for a Move Toward Higher Prices”. The other Streetinsider.com‘s article was titled “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” and posted on May 15, 2018.

Array BioPharma Inc. (NASDAQ:ARRY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: